CARDIAC AMYLOIDOSIS IN HEART FAILURE. CLINICAL SUSPICION, DIFFERENTIAL DIAGNOSIS, AND TREATMENT

Authors

Keywords:

cardiac amyloidosis; heart failure; transthyretin; immunoglobulin light chains; scintigraphy

Abstract

DOI: https://doi.org/10.46296/yc.v10i19.1025

Abstract

Background. Cardiac amyloidosis is an underdiagnosed cause of heart failure, particularly in older adults with preserved ejection fraction and unexplained ventricular wall thickening. Objective. To synthesize evidence on clinical red flags, the diagnostic pathway, and disease-modifying treatment for immunoglobulin light-chain (AL) and transthyretin (ATTR) amyloidosis. Methods. This structured narrative review used a targeted selection of guidelines, diagnostic studies, clinical trials, and regional documents available through August 20, 2026. Sources were selected for clinical relevance and synthesized qualitatively. Results. Unexplained ventricular wall thickening, conduction disorders, and extracardiac manifestations raise suspicion. Initial monoclonal protein testing includes serum and urine immunofixation and measurement of serum free light chains. In patients with compatible clinical and imaging findings, grade 2 or 3 myocardial uptake confirmed by single-photon emission computed tomography (SPECT) allows a nonbiopsy diagnosis of ATTR when monoclonal protein testing is negative. Suspected AL warrants prompt hematology assessment and tissue confirmation with amyloid typing. Trials of tafamidis, acoramidis, and vutrisiran demonstrated benefits across different outcomes in ATTR cardiomyopathy. In AL, adding daratumumab to plasma cell–directed therapy increased the rate of complete hematologic response. Conclusions. The diagnostic pathway should promptly identify possible AL and limit nonbiopsy diagnosis to patients who meet established ATTR criteria. Referral pathways should facilitate access to monoclonal protein testing, nuclear imaging, and tissue typing.

Keywords: cardiac amyloidosis; heart failure; transthyretin; immunoglobulin light chains; scintigraphy.

Downloads

Download data is not yet available.

References

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-68. doi:10.1093/eurheartj/ehab072.

Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076-126. doi:10.1016/j.jacc.2022.11.022.

González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94. doi:10.1093/eurheartj/ehv338.

Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J, et al. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. J Am Coll Cardiol. 2026;87(5):549-65. doi:10.1016/j.jacc.2025.09.004.

Kukreti V, Seftel M, Aguirre MA, Azzam M, Boedicker DD, Bumma N, et al. American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis. Blood Adv. 2026;10(14):5113-52. doi:10.1182/bloodadvances.2025017073.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-12. doi:10.1161/CIRCULATIONAHA.116.021612.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-16. doi:10.1056/NEJMoa1805689.

Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132-42. doi:10.1056/NEJMoa2305434.

Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33-44. doi:10.1056/NEJMoa2409134.

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46-58. doi:10.1056/NEJMoa2028631.

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis. Blood. 2026;148(9):1097-107. Publicación electrónica 12 may 2026. doi:10.1182/blood.2025032099.

Sociedad Ecuatoriana de Cardiología Núcleo Pichincha. Consenso ecuatoriano de diagnóstico y tratamiento de amiloidosis cardíaca [Internet]. 2024 [citado 12 nov 2026]. Disponible en: https://scardiopichincha.org/consenso-ecuatoriano-de-diagnostico-y-tratamiento-de-amiloidosis-cardiaca/

Published

2026-10-30

How to Cite

Morocho-Saldarriaga, K. F., Chávez-Ruiz, C. G., Carrillo-Saraguro, S. del R., Rea-Ambuludi, G. J., & Araujo-Briceño, M. E. (2026). CARDIAC AMYLOIDOSIS IN HEART FAILURE. CLINICAL SUSPICION, DIFFERENTIAL DIAGNOSIS, AND TREATMENT. REVISTA CIENTÍFICA MULTIDISCIPLINARIA ARBITRADA YACHASUN - ISSN: 2697-3456, 10(19), 1979–1988. Retrieved from https://www.editorialibkn.com/index.php/Yachasun/article/view/1116